These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Subconjunctival bevacizumab injection in treatment of pterygium. Besharati MR; Manaviat MR; Souzani A Acta Med Iran; 2011; 49(3):179-83. PubMed ID: 21681707 [TBL] [Abstract][Full Text] [Related]
8. Effect of subconjunctival bevacizumab on primary pterygium. Teng CC; Patel NN; Jacobson L Cornea; 2009 May; 28(4):468-70. PubMed ID: 19411971 [TBL] [Abstract][Full Text] [Related]
9. Bleb morphology and vascularity after trabeculectomy with intravitreal ranibizumab: a pilot study. Kahook MY Am J Ophthalmol; 2010 Sep; 150(3):399-403.e1. PubMed ID: 20570237 [TBL] [Abstract][Full Text] [Related]
10. A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO Study. Lalwani GA; Rosenfeld PJ; Fung AE; Dubovy SR; Michels S; Feuer W; Davis JL; Flynn HW; Esquiabro M Am J Ophthalmol; 2009 Jul; 148(1):43-58.e1. PubMed ID: 19376495 [TBL] [Abstract][Full Text] [Related]
11. Evaluation of injection frequency and visual acuity outcomes for ranibizumab monotherapy in exudative age-related macular degeneration. Dadgostar H; Ventura AA; Chung JY; Sharma S; Kaiser PK Ophthalmology; 2009 Sep; 116(9):1740-7. PubMed ID: 19643484 [TBL] [Abstract][Full Text] [Related]
12. Randomized controlled trial of subconjunctival bevacizumab injection in impending recurrent pterygium: a pilot study. Lekhanont K; Patarakittam T; Thongphiew P; Suwan-apichon O; Hanutsaha P Cornea; 2012 Feb; 31(2):155-61. PubMed ID: 22081150 [TBL] [Abstract][Full Text] [Related]
13. Ranibizumab for macular edema following branch retinal vein occlusion: six-month primary end point results of a phase III study. Campochiaro PA; Heier JS; Feiner L; Gray S; Saroj N; Rundle AC; Murahashi WY; Rubio RG; Ophthalmology; 2010 Jun; 117(6):1102-1112.e1. PubMed ID: 20398941 [TBL] [Abstract][Full Text] [Related]
14. Intravitreal ranibizumab for the primary treatment of choroidal neovascularization secondary to pathologic myopia. Lai TY; Chan WM; Liu DT; Lam DS Retina; 2009 Jun; 29(6):750-6. PubMed ID: 19357555 [TBL] [Abstract][Full Text] [Related]
15. A Phase IIIb study to evaluate the safety of ranibizumab in subjects with neovascular age-related macular degeneration. Boyer DS; Heier JS; Brown DM; Francom SF; Ianchulev T; Rubio RG Ophthalmology; 2009 Sep; 116(9):1731-9. PubMed ID: 19643495 [TBL] [Abstract][Full Text] [Related]
18. Ranibizumab for macular edema following central retinal vein occlusion: six-month primary end point results of a phase III study. Brown DM; Campochiaro PA; Singh RP; Li Z; Gray S; Saroj N; Rundle AC; Rubio RG; Murahashi WY; Ophthalmology; 2010 Jun; 117(6):1124-1133.e1. PubMed ID: 20381871 [TBL] [Abstract][Full Text] [Related]
19. Topical bevacizumab eyedrops for limbal-conjunctival neovascularization in impending recurrent pterygium. Wu PC; Kuo HK; Tai MH; Shin SJ Cornea; 2009 Jan; 28(1):103-4. PubMed ID: 19092418 [TBL] [Abstract][Full Text] [Related]
20. Efficacy of intralesional bevacizumab injection in decreasing pterygium size. Fallah Tafti MR; Khosravifard K; Mohammadpour M; Hashemian MN; Kiarudi MY Cornea; 2011 Feb; 30(2):127-9. PubMed ID: 20885313 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]